Personalized Therapy of Prostate Cancer
PDF

Keywords

Prostate Cancer
PSA BRCA1/2
Personalized Therapy

How to Cite

1.
Tizar F, El Kadmiri N. Personalized Therapy of Prostate Cancer. Health Sci. [Internet]. 2020 Oct. 26 [cited 2022 May 16];. Available from: https://mbmj.org/index.php/hs/article/view/282

Abstract

As prostate cancer is the second leading cause of death after lung cancer, several diagnostic strategies have been introduced in recent years. Among these prostate-specific antigens, it is widely recognized that this is the simplest and most common clinical endpoint - genetic instability is part of the oncogenic process. Gene mutations involved in DNA repair mechanisms may promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, abnormalities in DNA repair are primarily due to somatic or constitutional mutations in the BRCA1/2 genes. Treatment options for prostate cancer are currently widely discussed in the media and by urological associations. Focal therapy is expected to have the same oncological efficacy as whole gland therapy with fewer side effects. Accurate diagnosis with multiparametric magnetic resonance imaging (MRI). In this review, we examine the various studies described presently as the molecular targets for personalized prostate cancer therapy.

https://doi.org/10.15342/hs.2020.282
PDF

References

Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015 Jul 15;137(2):262-6. https://doi.org/10.1002/ijc.28940

Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol Curr Clin Pharmacol. 2006 Jan;1(1):119-28. https://doi.org/10.2174/157488406784111627

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34.https://doi.org/10.3322/caac.21551

Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. Jan-Mar 2017; 10(1):5-12.

Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000 Rev Epidemiol Sante Publique. 2003 Feb;51(1 Pt 1):3-30.

Salomon L, Ploussard G, Hennequin C, Richaud P, Soulié M. [Treatments around surgery of prostate cancer and surgery of recurrence]. Prog Urol. 2015 Nov;25(15):1086-107.https://doi.org/10.1016/j.purol.2015.08.009

Soulie M, Beuzeboc P, Richaud P, Villers A, Kassab Chahmi D, Bataillard A, et al. [Bulletin of synthesis 2005. Recommendations for clinical practice. Management of non metastatic prostate cancer]. Prog Urol. 2007; 17(4): 801–809. https://doi.org/10.1016/s1166-7087(07)92296-4

Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014 May;44(5):433-40. https://doi.org/10.1111/imj.12407

Chauvet B, Jacob T, Davin JL, Berger C, Vincent P, Reboul F. [Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate]. Bull Cancer Radiother. 1996;83(4):334-44.

Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70. https://doi.org/10.1073/pnas.83.10.3166

Lamy PJ, Brouillet JP, Bermont L, Fouillet G, Loric S. Relevance of total PSA and free PSA prescriptions Ann Biol Clin (Paris). 2018 Dec 1;76(6):659-663. https://doi.org/10.1684/abc.2018.1392

Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA. The role of BRCA1 and BRCA2 in prostate cancer. Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1445-59. https://doi.org/10.2741/4191

Sztupinszki Z, Diossy M, Krzystanek M, Borcsok J, Pomerantz MM, Tisza V, et al. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations. Clin Cancer Res. 2020 Jun 1;26(11):2673-2680. https://doi.org/10.1158/1078-0432.ccr-19-2135

Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10;35(20):2240-2250. https://doi.org/10.1200/jco.2016.69.4935

Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis. Prostate. 2019 Jun;79(8):880-895. https://doi.org/10.1002/pros.23795

Considine B, Petrylak DP. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer. Oncology (Williston Park). 2019 Apr 15;33(4):128-31.

Moatti JP. Personalized medicine: illusion or revolution? Med Sci (Paris). 2014 Nov;30 Spec No 2:4-7. https://doi.org/10.1051/medsci/201430s201

Flippot R, Massard C, Auclin E, Azria D, Bourien H, Rochigneux P, et at. “[The breakthrough of personalized medicine, new hopes and new challenges Bull Cancer. 2017 Sep;104(9):735-743.https://doi.org/10.1016/j.bulcan.2017.07.003

Lehmann-Che, B. Poirot, J.-C. Boyer, and A. Evrard, “Cancer genomics guide clinical practice in personalized medicine. Therapie. 2017 Sep;72(4):439-451. https://doi.org/10.1016/j.therap.2016.09.015

Toffart AC, Dhalluin X, Girard N, Chouaid C, Audigier-Valette C, Duruisseaux M, et al. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Med. 2015 Jan;41(1):164-5. https://doi.org/10.1007/s00134-014-3535-x

Cormier L, Créhange G. [Therapeutic innovations in urology for localized prostate cancer]. Cancer Radiother. 2017 Oct;21(6-7):442-446. https://doi.org/10.1016/j.canrad.2017.08.107

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2020 Tizar F & El Kadmiri N